insights_auto
展望： 58.8% 看涨·5.9% 看跌
前往“分析”标签页chevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
US$48.56
0.00%
(0.00) 1 天
US$49.10
arrow_upward
+1.11% (+0.54)today开盘前
休市： 11月5日, GMT-5 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 CRSP 生成关键数据洞见…
市值
47.10亿
平均成交量
145.51万
成交量
2.24万
52 周最高价
US$63.45
52 周最低价
US$44.12
每股收益
-US$4.75
Beta 版
1.49
流通股数
9700.10万
员工人数
393
市值
47.10亿
平均成交量
145.51万
成交量
2.24万
52 周最高价
US$63.45
52 周最低价
US$44.12
每股收益
-US$4.75
Beta 版
1.49
流通股数
9700.10万
员工人数
393
新闻报道
来自网络来源和新闻合作伙伴
The Globe and Mail
·
1天前
Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital
Yahoo Finance
·
2天前
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
资料
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Crispr Therapeutics AG简介